16142-03-3

Usage

Uses

Used in Pharmaceutical Industry:
[2-[2-[2-[2-(2-Methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]acetic acid is used as a PEG linker for improving the solubility and stability of drug molecules. The PEG spacer enhances the hydrophilicity of the drug, which can lead to better absorption and bioavailability. Additionally, the terminal carboxylic acid allows for the formation of stable amide bonds with primary amine groups on drug molecules, facilitating the creation of conjugates or prodrugs.
Used in Drug Delivery Systems:
In the field of drug delivery, [2-[2-[2-[2-(2-Methoxyethoxy)ethoxy]ethoxy]ethoxy]acetic acid is used as a component in the design of targeted drug delivery systems. The PEG spacer can be functionalized with targeting ligands, allowing for specific binding to receptors on diseased cells. This targeted approach can improve the efficacy of the drug and reduce side effects by minimizing exposure to healthy cells.
Used in Bioconjugation:
[2-[2-[2-[2-(2-Methoxyethoxy)ethoxy]ethoxy]ethoxy]acetic acid is used as a bioconjugation agent to attach biologically active molecules, such as peptides, proteins, or nucleic acids, to other molecules or surfaces. The stable amide bond formed between the terminal carboxylic acid and primary amine groups ensures that the conjugate remains intact under various conditions, allowing for a wide range of applications in research and therapeutic development.
Used in Diagnostics:
In the diagnostics industry, [2-[2-[2-[2-(2-Methoxyethoxy)ethoxy]ethoxy]ethoxy]acetic acid can be used to create PEGylated contrast agents for imaging techniques such as magnetic resonance imaging (MRI) or computed tomography (CT). The PEG spacer can improve the circulation time and reduce the immunogenicity of the contrast agents, leading to better imaging results and reduced side effects.
Used in Material Science:
[2-[2-[2-[2-(2-Methoxyethoxy)ethoxy]ethoxy]ethoxy]acetic acid can be utilized in the development of hydrogels and other biomaterials due to its hydrophilic PEG spacer and reactive carboxylic acid group. These materials can be tailored for various applications, such as tissue engineering, wound healing, and controlled release of bioactive molecules.

Upstream product

• 2615-15-8 pentaethylene glycol 
• 194281-47-5 2-{2-[2-(2-{2-[2-(tert-butyldimethylsilanyloxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy}ethanol 
• 23778-52-1 3,6,9,12,15-pentaoxahexadecanol 
• 79-08-3 bromoacetic acid 
• 79-11-8 chloroacetic acid 

Relevant academic research and scientific papers

CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self- immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

ALKYNYL INDAZOLE DERIVATIVE AND USE THEREOF

The main object of the present invention is to provide a novel compound which has a VEGF receptor tyrosine kinase inhibitory activity and is useful as an active ingredient for the treatment of diseases accompanying angiogenesis or edema, for example, age-related macular degeneration or the like. The present invention includes, for example, an alkynyl indazole derivative represented by the following general formula (I), a pharmaceutical acceptable salt thereof, and a medicine containing thereof.

Gold nanoparticles generated by thermolysis of "all-in-one" gold(i) carboxylate complexes

Consecutive synthesis methodologies for the preparation of the gold(i) carboxylates [(Ph3P)AuO2CCH2(OCH 2CH2)nOCH3] (n = 0-6) (6a-g) are reported, whereby selective mono-alkylation of diols HO(CH2CH 2O)nH (n = 0-6), Williamson ether synthesis and metal carboxylate (Ag, Au) formation are the key steps. Single crystal X-ray diffraction studies of 6a (n = 0) and 6b (n = 1) were carried out showing that the P-Au-O unit is essentially linear. These compounds were applied in the formation of gold nanoparticles (NP) by a thermally induced decomposition process and hence the addition of any further stabilizing and reducing reagents, respectively, is not required. The ethylene glycol functionalities, providing multiple donating capabilities, are able to stabilise the encapsulated gold colloids. The dependency of concentration, generation time and ethylene glycol chain lengths on the NP size and size distribution is discussed. Characterisation of the gold colloids was performed by TEM, UV/Vis spectroscopy and electron diffraction studies revealing that Au NP are formed with a size of 3.3 (±0.6) to 6.5 (±0.9) nm in p-xylene with a sharp size distribution. Additionally, a decomposition mechanism determined by TG-MS coupling experiments of the gold(i) precursors is reported showing that 1 st decarboxylation occurs followed by the cleavage of the Au-PPh 3 bond and finally release of ethylene glycol fragments to give Au-NP and the appropriate organics. The Royal Society of Chemistry 2012.